China NT Pharma Group Co., Ltd. ( (HK:1011) ) has shared an announcement.
China NT Pharma Group Co., Ltd. announced its audited annual results for the year ending December 31, 2024, revealing a significant financial loss. The company reported a total comprehensive loss of RMB 59,543,000, a slight improvement from the previous year’s loss of RMB 145,009,000. Revenue increased to RMB 37,960,000 from RMB 7,366,000 in 2023, but the company faced challenges with high finance costs and losses from fair value changes and deconsolidation of subsidiaries. These results highlight ongoing financial challenges and potential impacts on the company’s market positioning and stakeholder confidence.
More about China NT Pharma Group Co., Ltd.
China NT Pharma Group Co., Ltd. is involved in the pharmaceutical industry, focusing on the development, manufacturing, and distribution of pharmaceutical products. The company operates primarily in the Chinese market, offering a range of medical solutions and services.
YTD Price Performance: -11.11%
Average Trading Volume: 167,711
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$161.8M
For an in-depth examination of 1011 stock, go to TipRanks’ Stock Analysis page.